Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience

BACKGROUND: HER2/neu overexpression and/or amplification has been widely studied in a number of solid tumors, primarily in the breast. In gynecologic neoplasms, determination of HER2/neu status has not been well studied as a predictive biomarker in anti-HER2/neu treatment. METHODS: We systematically...

Descripción completa

Detalles Bibliográficos
Autores principales: Woo, Jennifer S., Apple, Sophia K., Sullivan, Peggy S., Rao, Jian-Yu, Ostrzega, Nora, Moatamed, Neda A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075405/
https://www.ncbi.nlm.nih.gov/pubmed/27770810
http://dx.doi.org/10.1186/s13000-016-0553-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075405/
https://www.ncbi.nlm.nih.gov/pubmed/27770810
http://dx.doi.org/10.1186/s13000-016-0553-8

Ejemplares similares